Skip to main content
. Author manuscript; available in PMC: 2022 Jun 14.
Published in final edited form as: Clin Infect Dis. 2021 Nov 2;73(9):e2729–e2738. doi: 10.1093/cid/ciaa806

Table 3.

Clinical Symptoms and Severity of Illness for Inpatient AGE cases, Overall and by Single and Multiple Pathogensa

AGE (n = 724) C. difficile(n = 120) Norovirus (n = 27) Campylobacter spp. (n = 22) Shigella/EIEC (n = 10) Salmonella spp. (n = 10) Rotavirus (n = 11) Multiple co-pathogens (n = 20)

Frequency of clinical symptoms, n (%)
 Fever 164/718 (23) 19/118 (16) 4/27 (15) 6/22 (27) 5/10 (50) 2/10 (20) 3/11 (27) 5/20 (25)
 Diarrhead 680/723 (94) 118/120 (98) 27/27 (100) 22/22 (100) 10/10 (100) 10/10 (100) 11/11 (100) 19/19 (100)
 Vomiting 378/724 (52) 56/120 (47) 23/27 (85) 7/22 (32) 5/10 (50) 1/10 (10) 8/11 (73) 12/20 (60)
 Only diarrhea 346/723 (48) 64/120 (53) 4/27 (15) 15/22 (68) 5/10 (50) 9/10 (90) 3/11 (27) 8/19 (42)
 Only vomiting 43/723 (6) 2/120 (2) 0 0 0 0 0 0
Duration of clinical symptoms in days, median (range; IQR)
 Fever at enrollment 2 (1–10; 1–4) 3 (1–8; 2–4) 1 (1–1; 1–1) 3 (3–5; 3–3) 2 (1–4; 2–2) 2 (1–2; 1–2) 1 (1–1; 1–1) 2 (1–8; 1–4)
 Diarrhea in 24 hours, episodes 5 (1–48; 4–8) 5 (1–30; 3–7) 5 (2–40; 4–15) 8 (3–30; 5–20) 7 (4–20; 4–10) 13 (4–30; 8–20) 10 (4–20; 5–15) 5 (2–20; 4–10)
 Vomiting in 24 hours, episodes 3 (1–118; 2–6) 3 (1–118; 2–6) 4 (1–20; 2–11) 2 (1–7; 1–3) 3 (1–4; 1–3) 4 (4–4; 4–4) 3 (1–15; 2–12) 2 (1–11; 2–5)
 Illness at enrollment 4 (1–10; 3–6) 4 (1–10; 3–7) 3 (1–10; 2–5) 4 (1–10; 4–6) 5 (2–9; 4–7) 5 (3–10; 4–5) 4 (2–7; 4–5) 4 (2–10; 3–5)
 Illness at follow-up 7 (1–15; 4–9) 7 (1–14; 4–9) 6 (1–12; 3–7) 8 (1–15; 6–9) 7 (2–11; 4–10) 7 (3–10; 7–10) 7 (2–12; 6–9) 5 (2–15; 4–7)
 Diarrhea at enrollment 4 (1–10; 2–5) 4 (1–10; 2–6) 2 (1–10; 2–5) 4 (1–10; 3–6) 5 (2–9; 3–6) 5 (3–10; 4–5) 4 (1–7; 2–5) 3 (1–10; 2–5)
 Diarrhea at follow-up 6 (1–15; 4–8) 6 (1–14; 4–8) 4 (1–10; 2–7) 7 (1–15; 6–9) 6 (2–11; 4–9) 7 (3–10; 7–10) 7 (1–12; 6–8) 5 (1–15; 3–6)
 Vomiting at enrollment 2 (1–10; 1–4) 2 (1–9; 1–4) 1 (1–6; 1–3) 1 (1–7; 1–2) 2 (1–4; 2–4) 4 (4–4; 4–4) 3 (1–3; 2–3) 2 (1–6; 2–3)
 Vomiting at follow-up 3 (1–13; 2–5) 3 (1–10; 2–6) 2 (1–10; 1–5) 3 (1–7; 2–4) 4 (1–6; 2–4) 6 (6–6; 6–6) 3 (3–6; 3–4) 3 (1–8; 2–4)
Severity of illness
Modified Vesikari Score (MVS), median (range)b 11 (4–19) 10 (4–18) 13 (8–17) 11 (7–17) 12 (10–16) 11 (8–17) 12 (9–18) 12 (7–16)
 Mild MVS, n (%) 38 (6) 4 (4) 0 0 0 0 0 0
 Moderate MVS, n (%) 293 (42) 56 (49) 7 (27) 8 (36) 2 (20) 5 (50) 3 (27) 9 (47)
 Severe MVS, n (%) 362 (52) 54 (47) 19 (73) 14 (63) 8 (80) 5 (50) 8 (73) 10 (53)
ICU stay, n (%) 89/724 (12) 20/120 (17) 2/27 (7) 1/22 (5) 2/10 (20) 0 1/11 (9) 3/20 (15)
Duration of ICU stay in days, median (range; IQR) 3 (1–38; 2–6) 2 (1–11; 2–6) 11 (10–12; 10–12) 2 (2–2; 2–2) 3 (1–4; 1–4) 0 2 (2–2; 2–2) 3 (3–4; 3–4)
Duration of hospital stay in days, median (range; IQR) 5 (1–196; 3–10) 6 (2–72; 3–16) 4 (1–66; 2–8) 4 (2–26; 3–7) 3 (1–26; 3–5) 4 (2–8; 3–6) 4 (2–38; 2–6) 5 (1–28; 3–8)
 Duration of hospital stay for community-onset cases 4 (1–95; 3–7) 5 (2–72; 3–8) 3 (1–13; 2–7) 4 (2–8; 3–6) 3 (1–26; 3–5) 4 (2–8; 3–6) 4 (2–38; 2–6) 5 (1–20; 3–7)
 Duration of hospital stay for hospital-onset cases 15 (1–196; 9–24) 20 (5–51; 11–24) 36 (6–66; 6–66) 26 (26–26; 26–26) 0 0 0 18 (8–28; 8–28)
23 hour stay, n (%) 86/724 (12) 12/120 (10) 6/27 (22) 2/22 (9) 1/10 (10) 0 1/11 (9) 3/20 (15)
Death, n (%)c 17/723 (2) 3/120 (3) 1/27 (4) 0 0 0 0 0
a

Pathogen-specific columns include AGE cases with single pathogen detections, independent of the other 5 pathogens in the table. Any co-detection (≥2) between the six pathogens are included in the multiple co-pathogens column.

b

If cases were missing data for certain measurements, a Vesikari score was not assigned, pathogen (% missing): AGE (4%), Norovirus (3%), C. difficile (6%), Salmonella (8%). Modified Vesikari scoring was defined as follows: Mild (0–6), Moderate (7–10), Severe (≥11). See supplementary appendix for scoring components.

c

Among these deaths, 14 occurred while hospitalized. Three deaths occurred within 1–12 days following discharge; one died in inpatient hospice, one died within 24 hours of transferring to inpatient palliative care, and one died after discharge. Deaths following discharge were ascertained when attempting the follow-up interview at 3–5 weeks post-enrollment.

Campylobacter spp. includes jejuni, coli, and upsaliensis. EIEC=Enteroinvasive E. coli

d

Diarrhea was defined as 3 or more loose stools within a 24 hour period